A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors.
The biotech, called Tenvie Therapeutics, launched Wednesday with $200 million from ARCH Venture Partners — one of Denali’s early investors — as well as F-Prime Capital, Mubadala Capital, and others. Denali has an undisclosed equity stake in the new company.
Tenvie is carrying over a collection of small molecule drugs that Denali had been developing but decided to discontinue work on. Executives teased the spinout at the J.P. Morgan Healthcare Conference last year.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
